Allogene Therapeutics
Jason D. has extensive experience in quality systems and compliance within the biotechnology and pharmaceutical sectors. Currently serving as Senior Manager at Allogene Therapeutics since November 2021, Jason has previously held positions such as Quality Systems Manager at BeiGene and Senior Quality Specialist at Lonza. Other notable roles include Quality Engineer at Amneal Pharmaceuticals, Quality Operations Analyst at Baxter International Inc., QC Chemist at Genemed Biotechnologies, and QC Associate at Genentech. Jason D. holds a Bachelor's degree in Biological Sciences from the University of California, Davis.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.